ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Anti-CD19 CAR-T Cells CABA-201

Also written as “CABA-201” and “CABA-201 following preconditioning with fludarabine and cyclophosphamide”.

Its studies are mostly in Dermatomyositis · Myasthenia Gravis · Scleroderma, Systemic · Pemphigus · Lupus Nephritis, led by Cabaletta Bio.

Drug pageAutologous Anti-CD19 CAR-T Cells CABA-201: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 16, 20236 company-led studies, 5 open or runningNext primary completion: Jul 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cabaletta Bio65 open or runningphase 3since Nov 16, 2023Jun 2, 2020Jul 2028phase 3 · NCT06154252

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 2, 2020First study: phase 2 study in PemphigusFirst studyNCT04422912 · 40 planned · United States
  2. Oct 23, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT06121297 · 28 planned · United States, Canada, Spain
  3. Nov 16, 2023Phase 3 study in MyositisNCT06154252 · 74 planned · United States, Germany, Italy and more
  4. Mar 19, 2024Phase 3 study in Scleroderma, SystemicNCT06328777 · 37 planned · United States
  5. Mar 21, 2024Phase 2 study in Myasthenia GravisNCT06359041 · 24 planned · United States
  6. Apr 22, 2025Phase 2 study in Multiple Sclerosis, Chronic ProgressiveNCT07006805

Ahead

  1. Jul 2028Primary completion: phase 3 study in MyositisNCT06154252
  2. Jan 2029Primary completion: phase 2 study in PemphigusNCT04422912
  3. Jul 2029Primary completion: phase 3 study in Scleroderma, SystemicNCT06328777
  4. Sep 2029Primary completion: phase 2 study in Myasthenia GravisNCT06359041

TargetBeta

CD19 →read by rule
“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-lymphocyte antigen CD19, coupled to a ”NCIt, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
rapcabtagene autoleucelNovartisphase 28

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07006805Multiple Sclerosis, Chronic Progressive2WithdrawnSep 20280
NCT06359041Myasthenia Gravis · United States2RecruitingSep 202924
NCT06328777Scleroderma, Systemic · United States3RecruitingJul 202937
NCT06154252Myositis · United States, Germany, Italy and more3RecruitingJul 202874
NCT06121297Lupus Erythematosus, Systemic · United States, Canada, Spain2RecruitingDec 202928
NCT04422912Pemphigus · United States2RecruitingJan 202940

How it is read

Names in the registry

  • “CABA-201”, 8 entries
  • “CABA-201 following preconditioning with fludarabine and cyclophosphamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.